Legacy Acquisition Corp. (LGC) Announces Intention to Tender Warrants
by Kristi Marvin on 2019-12-02 at 12:04pm

Warrant Tender Offer

Early this morning, Legacy Acquisition Corp. (LGC), filed a number of new documents, including a new preliminary proxy for their combination vote and a new presentation.  However, also filed was an 8-K that announced Legacy will pursue the possibility of effecting a tender offer for all its outstanding warrants post-business combination close.

A warrant tender is not guaranteed, but it’s definitely now on the table and if its in an 8-K, there’s a better than average possibility it will happen.  However, there are no details provided, such as at what price, but Legacy does have 30,000,000 million warrants outstanding for 1/2 share, or 15,000,000 shares upon exercise.

Side Letter

Additionally, Legacy entered into a Side Letter with Blue Impact regarding the forfeiture of Founder Shares in the event of trust redemptions.  The details of which are that if at the closing the funds in trust will be less than $270,000,000, then Legacy’s sponsor will surrender a number of its Founder shares (Class F common stock) according to the following calculation:

    • Cancellation of one (1) share of Class F common stock of the Purchaser for each $40 shortfall in the amount of funds available in the Trust Fund below $270,000,000, up to a maximum of 3,750,000 Forfeited Class F Shares.

The filing gives an example as well which I’ve summarized below:

  • For example, if after giving effect to the exercise of redemption rights by the redeeming stockholders of the Purchaser the amount of funds available in the Trust Fund at the time of the consummation of the Transactions is $260,000,000, then the number of Forfeited Class F Shares to be surrendered and forfeited by the Sponsor Designee shall be 250,000.
    • ($270,000,000 – $260,000,000 = $10,000,000/40 = 250,000 Class F shares to be cancelled)

Since the max that can be forfeited is 3,750,000 Founder Shares, that means that if $150 million is left in trust, the maximum amount of shares (3,750,000) will be forfeited and cancelled. $150,000,000/40 = 3,750,000 shares).  However, keep in mind that there is a condition to closing of a minimum $120 million.  As a reminder, Legacy’s Sponsor currently own 7,500,000 Founder shares (at IPO) and 17,500,000 private placement warrants.

All told, these changes are a positive. The warrant tender cleans up the post-combination cap table and (hopefully) at a decent price for warrant holders.  We’ll have to wait and see the tender offer details though.  Stay tuned.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved